系统回顾狗的非甾体类抗炎药物引起的不良反应。

文章的细节

引用

复制到剪贴板

Monteiro-Steagall BP,到处PV,拉塞尔斯双相障碍

系统回顾狗的非甾体类抗炎药物引起的不良反应。

J兽医实习生地中海。2013;9月- 10月27 (5):1011 - 9。doi: 10.1111 / jvim.12127。Epub 2013年6月19日。

PubMed ID

23782347 (在PubMed

]

文摘

本系统评价的目的是识别,评估,和批判性评估的证据质量的非甾体类抗炎药(非甾体抗炎药)在狗全身的副作用。原始英文发表在同行评议期刊上的前瞻性研究(1990 - 2012),非甾体抗炎药的安全管理报告数据的狗被搜索。必威国际app对于每一个研究,设计类型(I、II、III或IV)和评估的质量(O +, -)被评为。对于每一个药物,数量和一致性评级(* * *、* * *)和力量的证据(高、温和,低或极低)被确定和评估。证据的强度定义如何适用和相关结论到目标人群。六十四项研究符合入选标准。35(55%)研究和29例(45%)临床必威国际app试验中被确认。高强度的证据存在了carprofen, firocoxib, meloxicam;温和,deracoxib ketoprofen, robenacoxib;并为etodolac低。 Quality and consistency rating were as follows: carprofen (***/***), deracoxib (**/***), etodolac (*/unable to rate), firocoxib (***/**), ketoprofen (**/***), meloxicam (***/***), and robenacoxib (**/**), respectively. Adverse effects were detected in 35 studies (55%) and commonly included vomiting, diarrhea, and anorexia. Three studies (5%) reported a power analysis related to adverse effects of >/=80%. In randomized, placebo-controlled, blinded studies (n = 25, 39%), the incidence of adverse effects was not statistically different between treated and control dogs. Finally, most studies were not appropriately designed to determine the safety of NSAIDs, and involved a healthy nongeriatric population of research dogs.

DrugBank数据引用了这篇文章

药物

Robenacoxib